ALK-ABELLO A/S [CBOE] overview

ALK ( ALKB:DC / OMX: ALK B / AKBLF ): According to the company’s remuneration policy adopted at the company's Annual General Meeting on 14 March 2024 and in line with the company’s usual practice, the Board of Directors has passed a resolution to grant up to a total of 250,000 share-based instruments for the purpose of the company’s long-term incentive plan (LTIP) for the Board of Management and key employees for 2025. The objectives of the LTIP are to incentivise and reward long-term...

ALK ( ALKB:DC / OMX: ALK B / AKBLF ): ALK-Abelló A/S held its Annual General Meeting on 13 March 2025. The Annual General Meeting transacted the following business: Approval of the annual report 2024 and discharge of the Board of Directors and Board of Management Resolution not to declare ordinary dividend in accordance with the approved annual report for 2024 and to allocate the profits in accordance with the approved annual report Adoption of the remuneration report for 2024 Adoption of the...

ALK ( ALKB:DC / OMX: ALK B ) today announced that Health Canada has approved ALK’s ACARIZAX ® tablet for use in children, aged five to 11, with house dust mite (HDM) allergy. ACARIZAX ® is now indicated for treatment of moderate to severe HDM-induced allergic rhinitis, with or without conjunctivitis, in children, adolescents, and adults in Canada aged five to 65. Outside Europe, Canada is one of the most important markets for ALK’s respiratory tablet portfolio with sales growing...

ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff: The Board of Directors has previously granted share options and performance shares in ALK-Abelló A/S, re. company release no. 07/2022 of 24 March 2022. The right to share options and performance shares may be achieved in March 2025, provided that ALK...

ALK ( ALKB:DC / OMX: ALK B ) today announced that the US Food and Drug Administration (FDA) has approved ALK’s ODACTRA ® tablet for use in young children with house dust mite (HDM) allergy. ODACTRA ® is now indicated to treat HDM-induced allergic rhinitis, with or without conjunctivitis, in children aged five through 11, in addition to patients aged 12 through 65. ODACTRA ® is an allergy immunotherapy (AIT) tablet which dissolves under the tongue and helps patients reduce their allergy...

ALK ( ALKB:DC / OMX: ALK B / AKBLF ): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff as set forth in the attached announcement. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 Attachment Managers...

ALK ( ALKB:DC / OMX: ALK B / AKBLF ): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 13 March 2025 at 4:00 PM (CET) at ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached. ALK-Abelló A/S For further information please contact: Investor Relations : Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media : Maiken Riise Andersen, tel. +45 5054 1434...

ALK’s ( ALKB:DC / OMX: ALK B / AKBLF ) Board of Directors has approved the 2024 annual report. Following a robust performance in Q4, full-year results were in line with the latest outlook and represent the best results in the history of the company. ALK expects to continue its growth trajectory and earnings improvement in 2025. Q4 2024 highlights (Comparative figures are shown in brackets. Growth rates are stated in local currencies, unless otherwise indicated) Revenue increased by 11% to DKK...